Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NEW LISTING: Near-Term, Low-Cost Portuguese Tungsten Production in the EU (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cingulate Equity Warrants Exp 03rd Dec 2026 CINGW

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the... see more

Recent & Breaking News (NDAQ:CINGW)

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

GlobeNewswire 1 day ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

GlobeNewswire April 9, 2025

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

GlobeNewswire April 3, 2025

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

GlobeNewswire March 26, 2025

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

GlobeNewswire March 4, 2025

Final Study Completed for Cingulate's Lead Asset CTx-1301

GlobeNewswire January 7, 2025

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

GlobeNewswire December 23, 2024

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

GlobeNewswire November 7, 2024

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

GlobeNewswire October 8, 2024

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

GlobeNewswire September 12, 2024

Cingulate to Participate in Benzinga All Live Access Event

GlobeNewswire August 27, 2024

Cingulate Announces Adjournment of Special Meeting

GlobeNewswire August 23, 2024

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

GlobeNewswire August 15, 2024

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

GlobeNewswire August 13, 2024

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

GlobeNewswire June 28, 2024

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

GlobeNewswire June 25, 2024

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

GlobeNewswire June 25, 2024

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

GlobeNewswire May 21, 2024

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

GlobeNewswire May 8, 2024

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

GlobeNewswire April 30, 2024